LLY

1,066.82

+2.48%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

NVS

152.1

+0.44%↑

LLY

1,066.82

+2.48%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

NVS

152.1

+0.44%↑

LLY

1,066.82

+2.48%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

NVS

152.1

+0.44%↑

LLY

1,066.82

+2.48%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

NVS

152.1

+0.44%↑

LLY

1,066.82

+2.48%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

NVS

152.1

+0.44%↑

Начало・Списък с акции・Johnson and Johnson

Johnson and Johnson

Затворен

СекторЗдравеопазване

234.57 1.33

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

234.25

Максимум

235.09

Ключови измерители
By Trading Economics
Приходи	119M 5.2B
Продажби	-502M 24B
P/E Средно за сектора	26.526 49.701
EPS	2.7
Дивидентна доходност	2.29
Марж на печалбата	21.756
Служители	138,200
EBITDA	182M 6.4B

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+13.68% upside

Дивиденти
By Dow Jones
Дивидентна доходност Средно за сектора	2.29% 2.39%
Следващи печалби	15.07.2026 г.
Следваща дата на дивидент	9.06.2026 г.
Следваща дата на екс-дивидент	26.05.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-22B 551B
Предишно отваряне	233.24
Предишно затваряне	234.57

Настроения в новините

By Acuity

20%

80%

25 / 345 Класиране в Healthcare

Johnson and Johnson Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

24.04.2026 г., 13:27 ч. UTC

Придобивния, сливания и поглъщания

Johnson & Johnson to Acquire Atraverse Medical to Bolster Cardiac Device Portfolio

23.04.2026 г., 21:48 ч. UTC

Придобивния, сливания и поглъщания

Regeneron Shares Up on Trump Drug Pricing Deal -- Barrons.com

22.04.2026 г., 11:27 ч. UTC

Печалби

Intuitive Surgical Earnings Show Big Beats Don't Always Spark Stock Rallies -- Barrons.com

14.04.2026 г., 19:38 ч. UTC

Печалби

Johnson & Johnson Financial Chief Sees 'Clear Line of Sight' to Double-Digit Growth by 2030 -- Barrons.com

14.04.2026 г., 14:13 ч. UTC

Печалби

Johnson & Johnson Financial Chief Sees 'Clear Line of Sight' to Double-Digit Growth by 2030 -- Barrons.com

14.04.2026 г., 12:57 ч. UTC

Печалби

Johnson & Johnson Financial Chief Sees 'Clear Line of Sight' to Double-Digit Growth by 2030 -- Barrons.com

14.04.2026 г., 11:19 ч. UTC

Печалби

Johnson & Johnson Beats Earnings Estimates. Cancer Treatments Help Drive the Quarter. -- Barrons.com

14.04.2026 г., 10:34 ч. UTC

Печалби

Johnson & Johnson Stock Rises on Earnings Beat. These Segments Boosted the Quarter. -- Barrons.com

14.04.2026 г., 10:20 ч. UTC

Пазарно говорене

Печалби

J&J Sees Path to Double-Digit Growth by End of Decade -- Market Talk

14.04.2026 г., 10:20 ч. UTC

Пазарно говорене

Печалби

J&J's Tremfya Sales Continue to Surge -- Market Talk

14.04.2026 г., 10:20 ч. UTC

Печалби

Johnson & Johnson: With MedTech, Anticipate Additional Rounds of VBP in China Throughout Year, Heavier in Second Half of Year >JNJ

14.04.2026 г., 10:20 ч. UTC

Печалби

Johnson & Johnson: Expect Heavier Investment in First Half of 2026 Year >JNJ

14.04.2026 г., 10:20 ч. UTC

Печалби

Johnson & Johnson: With Innovative Medicine, Expect More Pronounced Sales Impact From Newly Launched Products as 2026 Progresses>JNJ

14.04.2026 г., 10:20 ч. UTC

Печалби

Johnson & Johnson Announce Planned Enterprise Business Review for Dec. 8, 2026 >JNJ

14.04.2026 г., 10:20 ч. UTC

Печалби

Johnson & Johnson: Anticipate Higher EPS Growth in Second Half of Year Vs First Half >JNJ

14.04.2026 г., 10:20 ч. UTC

Печалби

Johnson & Johnson: With MedTech, Expect Continued Acceleration of Newly Launched Products as Year Progresses With Normalized Seasonality >JNJ

14.04.2026 г., 10:20 ч. UTC

Печалби

Johnson & Johnson: With MedTech, Surgery Transformation Sales Headwinds Expected to Increase Through Year >JNJ

14.04.2026 г., 10:20 ч. UTC

Печалби

Johnson & Johnson Sees 2026 Adjusted Operational EPS $11.30-$11.50 Vs Prior View $11.28-$11.48 >JNJ

14.04.2026 г., 10:20 ч. UTC

Печалби

Johnson & Johnson: Anticipate Fairly Consistent Operational Sales Growth in First and Second Half With 53rd Week Affecting Second Half >JNJ

14.04.2026 г., 10:20 ч. UTC

Печалби

Johnson & Johnson: With Innovative Medicine, Anticipate Generic Competition for Opsumit (Second Half in U.S.) and Simponi (First Half in EU; Potentially Second Half in U. S.) >JNJ

14.04.2026 г., 10:20 ч. UTC

Печалби

Johnson & Johnson Sees 2026 Adj. Operational Sales Growth in Range of 5.6%-6.6% Vs Prior View 5.4%-6.4% >JNJ

14.04.2026 г., 10:20 ч. UTC

Печалби

Johnson & Johnson: 1Q Innovative Medicine Operational Sales Growth Driven Primarily by Darzalex, Carvykti, Erleada, Rybrevant/Lazcluze, Tremfya and Spravato >JNJ

14.04.2026 г., 10:20 ч. UTC

Печалби

Johnson & Johnson Raises 2026 View To Sales $100.3B-$101.3B Vs Prior View $100B-$101B >JNJ

14.04.2026 г., 10:20 ч. UTC

Печалби

Johnson & Johnson 1Q Orthopaedics Sales $2.38B >JNJ

14.04.2026 г., 10:20 ч. UTC

Печалби

Johnson & Johnson: 1Q MedTech Business Growth Driven Primarily by Electrophysiology Products, Abiomed, Shockwave as Well as Trauma >JNJ

14.04.2026 г., 10:20 ч. UTC

Печалби

Johnson & Johnson Sees 2026 Operational Sales of $99.7B-$100.7B Vs Prior View $99.5B-$100.5B>JNJ

14.04.2026 г., 10:20 ч. UTC

Печалби

Johnson & Johnson 1Q Adj EPS $2.70 >JNJ

14.04.2026 г., 10:20 ч. UTC

Печалби

Johnson & Johnson: New Treatment for Bladder Cancer Inlexzo Is Outperforming All Recent Launches Based on Unique Patients Treated in First 6 Months of Approval >JNJ

14.04.2026 г., 10:20 ч. UTC

Печалби

Johnson & Johnson 1Q U.S. Sales $13.33B >JNJ

14.04.2026 г., 10:20 ч. UTC

Печалби

Johnson & Johnson 1Q International Sales $10.73B >JNJ

Сравнение с други в отрасъла

Ценова промяна

Johnson and Johnson Прогноза

Ценова цел

By TipRanks

13.68% нагоре

12-месечна прогноза

Среден 266.4 USD 13.68%

Висок 285 USD

Нисък 250 USD

Според 17 анализатори от Wall Street, предложили 12-месечна ценова цел за Johnson and Johnson през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

17 ratings

Купи

Задържане

Продай

Според 17 анализатори, дали борсови рейтинги на Johnson and Johnson през последните 3 месеца.

Настроение

By Acuity

25 / 345 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Johnson and Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company has a collaboration agreement with Stand Up To Cancer for research testing a combination of teclistamab and daratumumab to treat a rare disease AL amyloidosis. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.